DiaPep277 DeveloGen

Current Opinion in Investigational Drugs

Volumn 6, Issue 10, 2005, Pages 1043-1050

  Giannoukakis, Nick ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AVE 0277; AVE 277; C PEPTIDE; DIACCINE; DIAPEP 277; GAD 65; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN 60; INSULIN; MONOCLONAL ANTIBODY CD3; NBI 6024; OKT 3; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES CONTROL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; NONHUMAN; OUTCOMES RESEARCH; PANCREAS ISLET; PATIENT MONITORING; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; T LYMPHOCYTE;

ANIMALS; CLINICAL TRIALS, PHASE II; DIABETES MELLITUS, TYPE 1; DRUG INDUSTRY; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 27544460098     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. 211250 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N ENGL J MED 1993 329 14 977-986
2. 385159 Peptor reports positive interim phase II data in diabetes trial and considers IPO plans. Peptor Ltd PRESS RELEASE 2000 September 07
3. 430694 Lancet study shows DiaPep277 arrests progression of type I diabetes. Peptor Ltd PRESS RELEASE 2001 November 26
4. 431104 β-Cell function in now-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR LANCET 2001 368 9295 1749-1753
5. 434320 Genetics, Pathogenesis, Prevention and Therapy of Type I and Type II Diabetes - Sixth International Meeting, Erice, Italy. Adorini L IDDB MEETING REPORT 2001 December 07-12
6. 459619 Aventis and Peptor Ltd sign agreement for the license, development and commercialisation of new diabetes therapy. Aventis SA PRESS RELEASE 2002 July 30
7. 463419 Molecular aspects of the etiology of type I diabetes mellitus. Eisenbarth GS J DIABETES COMPLICATIONS 1993 7 2 142-150
8. 463433 Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. DIABETES 1997 46 11 1829-1839
9. 463631 The NOD mouse model of type 1 diabetes: As good as it gets? Atkinson MA, Leiter EH NAT MED 1999 5 6 601-604
10. 475499 Peptide injection prevents progression of diabetes. PHARMACEUTIC J 2001 267 7176 767-773
11. 498336 Preservation of C-peptide and induction of Th2 cytokines in type 1 diabetes newly diagnosed adults vaccinated with DisPep277. Elias D, Metzger M, Avron A, Tamir M, Raz I DIABETOLOGIA 2000 43 Suppl 1 A105
12. 498340 Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Elias D, Cohen IR DIABETES 1995 44 9 1132-1138
13. 498341 Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various β-cell antigens. Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Konen-Waisman S, Cohen IR DIABETES 1997 46 5 758-764
14. 498342 NOD mouse diabetes: The ubiquitous mouse Hsp60 is a β-cell target antigen of autoimmune T cells. Birk OS, Elias D, Weiss AS, Rosen A, van-der Zee R, Walker MD, Cohen IR J AUTOIMMUN 1996 9 2 159-166
15. 498343 The Hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin. Elias D, Cohen IR DIABETES 1996 459 1168-1172
16. 498345 Islet T cells secreting IFNγ in NOD mouse diabetes: Arrest by p277 peptide treatment. Ablamunits V, Elias D, Reshef T, Cohen IR J AUTOIMMUN 1998 11 1 73-81
17. 498349 T cell proliferative responses of type 1 diabetes patients and healthy individuals to human Hsp60 and its peptides. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR J AUTOIMMUN 1999 12 2 121-129.
18. 498353 Peptide therapy for diabetes in NOD mice. Elias D, Cohen IR LANCET 1994 343 8899 704-706
19. 498356 Regulation of NOD mouse autoimmune diabetes by T cells that recognize a TCR CDR3 peptide. Elias D, Tikochinski Y, Frankel G, Cohen IR INT IMMUNOL 1999 11 6 957-966
20. 498361 Production and purification of a recombinant human Hsp60 epitope using the cellulose-binding domain in Escherichia coli. Shpigel E, Elias D, Cohen IR, Shoseyov O PROTEIN EXPR PURIF 1998 14 2 185-191
21. 498362 Treatment of NOD diabetes with a novel peptide of the Hsp60 molecule induces Th2-type antibodies. Bockova J, Elias D, Cohen IR J AUTOIMMUN 1997 10 4 323-329
22. 498363 Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein. Elias D, Marcus H, Reshef T, Ablamunits V, Cohen IR EUR J IMMUNOL 1995 25 10 2851-2857
23. 498364 Autoimmune diabetes induced by the β-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. Elias D, Prigozin H, Polak N, Rapoport M, Lohse AW, Cohen IR DIABETES 1994 43 8 992-998
24. 498432 A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Bekker PJ CANCER 2003 97 3 887-892
25. 498435 Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ J BONE MINER RES 2003 18 5 852-858
26. 519619 Protective effect of neonatal oral administration of DiaPep277 on diabetes type 1 in bio-breeding diabetes-prone rats. Brugman S, Visser J, Klatter F, Elias D, Bos N, Rozing J DIABETOLOGIA 2003 46 2 Suppl 2 A181
27. 539004 DeveloGen AG and Peptor Ltd shareholders approve merger. DeveloGen AG PRESS RELEASE 2004 May 17
28. 539012 Aventis ends Peptor collaboration. Aventis SA PRESS RELEASE 2004 May 17
29. 583263 Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. ANN INTERN MED 1998 128 7 517-523
30. 583354 Insulin autoimmunity: Prediction/precipitation/prevention type 1A diabetes. Eisenbarth GS, Moriyama H, Robles DT, Liu E, Yu L, Babu S, Redondo M, Gottlieb P, Wegmann D, Rewers M AUTOIMMUN REV 2002 1 3 139-145
31. 606973 Neonatal oral administration of DiaPep277, combined with hydrolysed casein diet, protects against type 1 diabetes In BB-DP rats. An experimental study. Brugman S, Klatter FA, Visser J, Bos NA, Elias D, Rozing J DIABETOLOGIA 2004 47 7 1331-1333
32. 606985 Company pipeline. DeveloGen AG COMPANY WORLD WIDE WEB SITE 2005 June 13
33. 609291 Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L et al N ENGL J MED 2005 352 25 2598-2608
34. Ala-Ala results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA DIABETES 2005 54 6 1763-1769
35. 613102 World Heart Corporation announces successful results of tender offers to amend and exchange warrants and debentures. World Heart Corporation PRESS RELEASE 2005 July 19
36. 616178 Islet cell autoantigens in insulin-dependent diabetes. Atkinson MA, Maclaren NK J CLIN INVEST 1993 92 4 1608-1616
37. 616180 Autoantigens in type 1 diabetes mellitus. Dotta F, Anastasi E, Tiberti C, Di Mario U J ENDOCRINOL INVEST 1994 17 7 497-508
38. 616181 T-cell recognition of β-cell autoantigens in insulin-dependent diabetes mellitus. Kallan AA, de Vries RR, Roep BO APMIS 1996 104 1 3-11
39. 616183 Islet cell autoantigens in type 1 diabetes. Christie MR EUR J CLIN INVEST 1996 26 10 827-838
40. 616184 Cellular and molecular roles of β cell autoantigens, macrophages and T cells in the pathogenesis of autoimmune diabetes. Yoon JW, Jun HS ARCH PHARM RES 1999 22 5 437-447
41. 616185 Multiple genes/multiple autoantigens role in type 1 diabetes. Abiru N, Eisenbarth GS CLIN REV ALLERGY IMMUNOL 2000 18 1 27-40
42. 616186 International workshop on lessons from animal models for human type 1 diabetes: Analyzing target autoantigens of humoral immunity in nonobese diabetic mice. Bonifacio E, Atkinson M, Eisenbarth G, Serreze D, Kay TW, Lee-Chan E, Singh B ANN NY ACAD SCI 2002 958 1-2
43. 616187 Tolerance to islet autoantigens in type 1 diabetes. Bach JF, Chatenoud L ANNU REV IMMUNOL 2001 19 131-161
44. 616188 Prediction and prevention strategies in type 1 diabetes. Eisenbarth G MT SINAI J MED 1991 58 4 274-279
45. 616193 Future trends in clinical islet transplantation. Burridge PW, Shapiro AM, Ryan EA, Lakey JR TRANSPLANT PROC 2002 34 8 3347-3348
46. 616194 Pancreatic islet transplantation in the treatment of diabetes mellitus. Shapiro AM, Ryan EA, Lakey JR BEST PRACT RES CLIN ENDOCRINOL METAB 2001 15 2 241-264
47. 616195 Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens. Weiner HL, Zhang ZJ, Khoury SJ, Miller A, al-Sabbagh A, Brod SA, Lider O, Higgins P, Sobel R, Nussenblatt RB et al ANN NY ACAD SCI 1991 636 227-232
48. 616196 Treatment of autoimmune diseases by oral tolerance to autoantigens. Weiner HL AUTOIMMUNITY 1993 15 Suppl 6-7
49. 616271 Treatment of autoimmune diseases by oral tolerance to autoantigens. Weiner HL, Miller A, Khoury SJ, Zhang ZJ, al-Sabbagh A, Brod SA, Lider O, Higgins P, Sobel R, Matsui M et al ADV EXP MED BIOL 1995 371B 1217-1223
50. 616274 Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, Gienapp IE, Meyer A, Cox KL, Javed N CLIN IMMUNOL IMMUNOPATHOL 1996 80 3 Pt 2 S31-S39
51. 616276 Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS NATURE 2005 435 7039 220-223
52. 616277 Comparative study of oral versus subcutaneous B:9-23 insulin peptide in BALB/c mice as an experimental model for autoimmune diabetes. Devendra D, Paronen J, Liu E, Moriyama H, Taylor R, Miao D, Yu L, Eisenbarth G ANN NY ACAD SCI 2004 1029 331-333
53. 616279 Differential immune induction with subcutaneous versus oral administration of a diabetogenic insulin peptide in the NOD mouse. Devendra D, Paronen J, Liu E, Moriyama H, Miao D, Yu L, Eisenbarth GS ANN NY ACAD SCI 2004 1029 328-330
54. 616280 Animal models of insulin-dependent diabetes. Liu E, Yu L, Moriyama H, Eisenbarth GS METHODS MOL MED 2004 102 195-212
55. 616281 Differential immune response to B:9-23 insulin 1 and insulin 2 peptides in animal models of type 1 diabetes. Devendra D, Paronen J, Moriyama H, Miao D, Eisenbarth GS, Liu E J AUTOIMMUN 2004 23 1 17-26
56. 616282 Insulin autoimmunity: Immunogenetics/immunopathogenesis of type 1A diabetes. Eisenbarth GS ANN NY ACAD SCI 2003 1005 109-118
57. 616287 Insulin-specific tolerance in diabetes. Gottlieb PA, Eisenbarth GS CLIN IMMUNOL 2002 102 1 2-11
58. 616291 It's insulin. Wegmann DR, Eisenbarth GS J AUTOIMMUN 2000 15 3 286-291
59. 616293 Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR PROC NATL ACAD SCI USA 1990 87 4 1576-1580
60. 616294 Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR PROC NATL ACAD SCI USA 1991 88 8 3088-3091
61. g7. Reizis B, Eisenstein M, Bockova J, Konen-Waisman S, Mor F, Elias D, Cohen IR INT IMMUNOL 1997 9 1 43-51
62. 616297 Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitus. Giannoukakis N, Trucco, M REV ENDOCR METAB DISORD 2003 4 4 369-380
63. 616299 Gene- and cell-based therapeutics for type I diabetes mellitus. Bottino R, Lemarchand P, Trucco M, Giannoukakis N GENE THER 2003 10 10 875-889
64. 616322 Current status of islet cell transplantation. Oberholzer J, Shapiro AM, Lakey JR, Ryan EA, Rajotte RV, Korbutt GS, Morel P, Kneteman NM ADV SURG 2003 37 253-282
65. 616323 Risks and side effects of islet transplantation. Ryan EA, Paty BW, Senior PA, Shapiro AM CURR DIAB REP 2004 4 4 304-309
66. 616324 Implications of the Diabetes Control and Complications Trial. American Diabetes Association DIABETES CARE 2002 25 S25-S27